Piramal Pharma Ltd
Piramal Pharma Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
2 of 3 strong
The short version
CDMO business is expected to drive significant margin expansion, with a target EBITDA margin of 25% by FY30, driven largely by improved utilization at overseas facilities and a differentiated product mix including more innovator products. Piramal Pharma started FY '27 strong with 17% revenue growth and 72% EBITDA growth YoY, signaling positive momentum.
From Piramal Pharma Ltd's Q1 FY27 earnings-call transcript · updated 23 Sept 2026.
Revenue & Sales Performance
- CDMO business is expected to drive significant margin expansion, with a target EBITDA margin of 25% by FY30, driven largely by improved utilization at overseas facilities and a differentiated product mix including more innovator products. (Page 17)
- Complex hospital generics (CHG) business growth includes both organic and acquisitions (e.g., Canalog), with market share gains in various geographies, particularly ex-US, contributing to growth. The company expects continued positive momentum in CHG in FY27. (Pages 17, 12)
- Consumer healthcare business expects margin expansion over the next few years, supported by brand momentum, channel expansion, premiumization, and disciplined pricing. (Page 17, 5)
2 more points management made on revenue & sales performance
Profitability & Margins
See what Piramal Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Annual capex guidance for FY27 is USD 120 million to USD 135 million; about USD 21 million spent so far (Page 16).
- Lexington sterile injectable capacity expansion is on track for completion by end of calendar year 2027 (Page 16).
- Riverview facility expansion completed, adding commercial-scale payload-linker development and manufacturing site with advanced capabilities; less than USD 5 million invested for specific linker payload room (Pages 9 and 15).
- Combined $90 million expansion program at Riverview and Lexington strengthening integrated ADC platform, including payload-linker manufacturing and sterile fill-finish capabilities (Page 3).
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Piramal Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Piramal Pharma began FY27 with a stronger opening order book compared to previous periods.
- The company referenced this stronger opening order book during the last investor call.
- There may be some ups and downs in order flow between quarters depending on delivery patterns.
- Management is maintaining the original full-year guidance without revision at this stage.
2 more points management made on order book & pipeline
Piramal Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹2.8K Cr, net loss ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Piramal Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
- Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
- RPG Life Sciences Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹195.7 crores, up 15.8% YoY (Q1 FY26: ₹168.9 crores) [Page 18] . Key concall takeaways from RPG Life Sciences Ltd's Q1 FY27…
- SMS Pharmaceuticals Ltd (Q1 FY27)
Q1FY27 revenue from operations: ₹207 crore, up 6% YoY (Page 6, 5) . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY27 earnings call — and how it…
Frequently Asked Questions
What were Piramal Pharma Ltd Q1 FY27 results?
CDMO business is expected to drive significant margin expansion, with a target EBITDA margin of 25% by FY30, driven largely by improved utilization at overseas facilities and a differentiated product mix including more innovator products. Piramal Pharma started FY '27 strong with 17% revenue growth and 72% EBITDA growth YoY, signaling positive momentum.
What is Piramal Pharma Ltd share price analysis?
Piramal Pharma Ltd currently shows a below-average growth signal. The stock trades at a P/E of N/A with a market cap of ₹27,713 Cr. Investors should review the full earnings analysis for detailed insights.
Is Piramal Pharma Ltd planning capital expenditure?
Annual capex guidance for FY27 is USD 120 million to USD 135 million; about USD 21 million spent so far (Page 16).
Keep Piramal Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.